CBB1007 | 1379573-92-8

• 物质功能分类: 生物化工 - 生化试剂 - 激动剂抑制剂
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: CBB1007
• 英文别名: Methyl 3-[4-(4-carbamimidoylbenzoyl)piperazine-1-carbonyl]-5-[(4-carbamimidoylpiperazin-1-yl)methyl]benzoate；methyl 3-[4-(4-carbamimidoylbenzoyl)piperazine-1-carbonyl]-5-[(4-carbamimidoylpiperazin-1-yl)methyl]benzoate
• CAS: 1379573-92-8
• 化学式: C₂₇H₃₄N₈O₄
• 分子量: 534.618
• InChiKey: IBVRETRIDAQSEM-UHFFFAOYSA-N

物化性质

• 溶解度：
  溶于二甲基亚砜

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  39
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  173
• 氢给体数：
  4
• 氢受体数：
  7

制备方法与用途

生物活性

CBB1007 可渗透入细胞，是 hLSD1 的选择性抑制剂，其 IC50 值为 5.27 μM。

文献信息

• [EN] METHODS OF CULTURING AND/OR EXPANDING STEM CELLS AND/OR LINEAGE COMMITTED PROGENITOR CELLS USING AMIDO COMPOUNDS<br/>[FR] PROCÉDÉS DE CULTURE ET/OU D'EXPANSION DE CELLULES SOUCHES ET/OU DE CELLULES PROGÉNITRICES DÉTERMINÉES D'UNE LIGNÉE À L'AIDE DE COMPOSÉS AMIDO
  申请人：IDEAYA BIOSCIENCES INC

  公开号：WO2020018848A1

  公开（公告）日：2020-01-23

  Provided are methods for expanding stem cells and/or lineage committed progenitor cells, such as hematopoietic stems cells and/or lineage committed progenitor cells, at least in part, by using compounds that antagonize AhR. The compounds are represented by formulae (I) (II) (III) (IV), wherein the letters and symbols a, b, c, d, e, f, g, Z, R1b, R2a and R2b have the meanings provided in the specification. Also provided are compositions comprising stem cells and/or lineage committed progenitor cells expanded by methods disclosed herein and methods for the treatment of diseases treatable by same.

  提供了一种扩增干细胞和/或系谱承诺的前体细胞的方法，例如造血干细胞和/或系谱承诺的前体细胞，至少部分地通过使用拮抗AhR的化合物。这些化合物由公式 (I) (II) (III) (IV) 表示，其中字母和符号 a、b、c、d、e、f、g、Z、R1b、R2a 和 R2b 在说明书中有提供的含义。还提供了包含通过本文披露的方法扩增的干细胞和/或系谱承诺的前体细胞的组合物，以及用于治疗可通过相同方法治疗的疾病的方法。
• Novel Suicidal LSD1 Inhibitors Targeting SOX2-Expressing Cancer Cells
  申请人：THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BE HALF OF THE UNIVERSITY OF N

  公开号：US20160120862A1

  公开（公告）日：2016-05-05

  Disclosed are inhibitors of lysine-specific demethylase I (LSD1); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating cancers characterized by the presence of Sox2 using the compounds and compositions Also disclosed are methods of treating cancers characterized by the presence of Sox2 using inhibitors of LSD1 and/or histone deacetylation I (HDAC1). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  本发明涉及一种赖氨酸特异性去甲基化酶I（LSD1）的抑制剂，合成该化合物的方法，包含该化合物的制药组合物以及使用该化合物和组合物治疗存在Sox2的癌症的方法。本发明还涉及使用LSD1和/或组蛋白去乙酰化酶I（HDAC1）的抑制剂治疗存在Sox2的癌症的方法。本摘要旨在作为搜索特定领域的扫描工具，不限制本发明。
• Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
  申请人：CHILDREN'S MEDICAL CENTER CORPORATION

  公开号：US10669528B2

  公开（公告）日：2020-06-02

  The methods and compositions described herein relate to producing, expanding, enriching, and/or maintaining hematopoietic stem cells ex vivo by treating the cells with an agent(s) that exhibits two or more activities selected from modulation of histone methylation; inhibition of TGFβ signaling; inhibition of p38 signaling; activation of canonical Wnt signaling; and modulation of histone acetylation. In some embodiments, the technology described herein relates to transplantation of hematopoietic stem cells.

  本文所述的方法和组合物涉及用一种或多种药剂处理体内外造血干细胞，以产生、扩增、富集和/或维持造血干细胞，这些药剂具有两种或多种活性，选自组蛋白甲基化调节；TGFβ信号转导抑制；p38信号转导抑制；典型Wnt信号转导激活；组蛋白乙酰化调节。在某些实施方案中，本文所述技术涉及造血干细胞的移植。
• METHODS AND COMPOSITIONS RELATING TO HEMATOPOIETIC STEM CELL EXPANSION
  申请人：Children's Medical Center Corporation

  公开号：EP3429603B1

  公开（公告）日：2021-12-29
• METHODS AND COMPOSITIONS RELATING TO HEMATOPOIETIC STEM CELL EXPANSION, ENRICHMENT, AND MAINTENANCE
  申请人：CHILDREN'S MEDICAL CENTER CORPORATION

  公开号：US20180187156A1

  公开（公告）日：2018-07-05

  The methods and compositions described herein relate to producing, expanding, enriching, and/or maintaining hematopoietic stem cells ex vivo by treating the cells with an agent(s) that exhibits two or more activities selected from modulation of histone methylation; inhibition of TGFβ signaling; inhibition of p38 signaling; activation of canonical Wnt signaling; and modulation of histone acetylation. In some embodiments, the technology described herein relates to transplantation of hematopoietic stem cells.